Prothena Corporation plc (PRTA)
| Market Cap | 495.80M -36.7% |
| Revenue (ttm) | 9.68M -92.8% |
| Net Income | -244.09M |
| EPS | -4.53 |
| Shares Out | 53.83M |
| PE Ratio | n/a |
| Forward PE | 37.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 584,453 |
| Open | 9.40 |
| Previous Close | 9.31 |
| Day's Range | 9.00 - 9.54 |
| 52-Week Range | 4.32 - 14.34 |
| Beta | -0.28 |
| Analysts | Buy |
| Price Target | 19.00 (+106.3%) |
| Earnings Date | Feb 19, 2026 |
About PRTA
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau a... [Read more]
Financial Performance
In 2025, Prothena Corporation's revenue was $9.68 million, a decrease of -92.83% compared to the previous year's $135.16 million. Losses were -$244.09 million, 99.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for PRTA stock is "Buy." The 12-month stock price target is $19.0, which is an increase of 106.30% from the latest price.
News
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena earned a $50 million milestone from Novo Nordisk related to enrollment in the Phase 3 CLEOPATTRA trial evaluating coramitug for ATTR-CM.
Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution
Prothena Corporation plc is maintained at a Hold rating due to mixed phase 2 data and long timelines for key programs. PRTA's leading assets, prasinezumab (Parkinson's disease) and coramitug (ATTR-CM)...
Prothena Announces up to $100 Million Share Repurchase Plan
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced its Board has authorized a Share Repurchase Plan so it may repurchase up to $100 million of the Company's outstanding shares.
Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript
Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights.
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that it will report its fourth quarter and full year 2025 financial results on Thursday 2/19/26 with a conference call at 4:30pm ET.
Prothena Announces Board of Directors Update
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein...
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025.
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Phase 2 clinical data for coramitug, a potential first-in-class amyloid depleter antibody, for the treatment of ATTR-CM published in Circulation.
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the third quarter and first nine months of 2025 and provided business highlights.
Prothena to Report Third Quarter 2025 Financial Results on November 6
DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena will report its third quarter 2025 financial results on Thursday November 6, 2025, after the close of the U.S. financial markets.
Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--PRTA announced that BMS communicated that the FDA granted Fast Track Designation to BMS-986446, an anti-tau antibody in P2 for Alzheimer's disease.
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein...
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program.
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the second quarter and first six months of 2025 and provided business highlights.
Prothena to Report Second Quarter 2025 Financial Results on August 4
DUBLIN--(BUSINESS WIRE)--Prothena today announced that it will report its second quarter and first six months of 2025 financial results on August 4, 2025.
Prothena Announces Corporate Restructuring
DUBLIN--(BUSINESS WIRE)--Prothena announced that the Company has initiated an approximate 63% reduction in its workforce.
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson's disease.
Why Is Prothena Stock Trading Lower On Tuesday?
Prothena Corporation plc PRTA released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis on Friday.
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
DUBLIN--(BUSINESS WIRE)--Prothena today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint.
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the first quarter of 2025 and provided business highlights.
Prothena to Report First Quarter 2025 Financial Results on May 8
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025.
Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript
Prothena Corporation plc (NASDAQ:PRTA) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Gene Kinney - President a...